Related Experiment Video
Updated: May 31, 2026

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
Published on: December 1, 2023
sweelin®, a novel sweet protein, does not affect blood glucose and insulin levels - a double-blind, crossover,
Yael Lifshitz1, Rotem Saban1, Shira Paz1
1Amai Proteins Ltd., Rehovot 7670402, Israel.
Abstract:
A novel hyper-sweet protein, sweelin®, enables sugar reduction without compromising taste. This double-blind, randomized, crossover study evaluated the effect of sweelin® on blood glucose, insulin and GLP-1 levels compared to stevia and dextrose in healthy adults. In this study, subjects consumed sweelin® (0.051 g), stevia Reb-M (0.225 g) or dextrose (75 g) in beverages matched for sweetness levels. Blood samples were collected at baseline and during 120-min post consumption. Each participant (n = 19) consumed each of the three beverages in a randomized order. At every time point after consumption, as well as iAUC, glucose and insulin levels were significantly lower following sweelin® consumption compared to dextrose (p < 0.0001), and not different from stevia. Overall, the findings indicate that sweelin®, is well tolerated and does not increase blood glucose, insulin or GLP-1 levels in healthy individuals, and suggest that sweelin® may serve as a metabolically neutral alternative for individuals seeking to reduce sugar intake. This trial was registered at clinicaltrials.gov (identifier code: NCT06520293).
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
06:21Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
Related Concept Videos
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Hyperglycemia